Monday, 9 July 2012
Summary basis of decision for Caprelsa
Health Canada has issued a Notice of Compliance to AstraZeneca Canada Inc. for the drug product, Caprelsa. Caprelsa contains the medicinal ingredient vandetanib which is a receptor tyrosine kinase inhibitor. It is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment